Showing 71-80 of 1039 results for "".
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- And the ASDS Stegman Award Goes to … Susan H. Weinkle, MDhttps://practicaldermatology.com/news/and-the-asds-stegman-award-goes-to-susan-h-weinkle-md/2458017/Bradenton, FL-based dermatologist Susan H. Weinkle, MD received the Samuel J. St
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://practicaldermatology.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Partial Irreversible Electroporation May Help Extinguish Burn Scars Before They Starthttps://practicaldermatology.com/news/partial-irreversible-electroporation-may-help-extinguish-burn-scars-before-they-start/2458470/A new non-invasive method may help prevent burn scarring caused by the proliferation of collagen cells, report researchers from Tel Aviv University and Harvard University in the J
- Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeanthttps://practicaldermatology.com/news/joseph-c-papa-assumes-role-of-chairman-and-chief-executive-officer-of-valeant/2458580/Joseph C. Papa has assumed the role of Chairman and Chief Executive Officer at Valeant Pharmaceuticals International, Inc. As previously announced, Joseph C. Papa succeeds J. Michael Pearson. &quo